View in EDS

436TiP COLSTAR: Randomized, open-label, multicentre, phase III study comparing futuximab/modotuximab plus trifluridine/tipiracil to trifluridine/tipiracil in KRAS/NRAS and BRAF wild type (wt) metastatic colorectal cancer (mCRC) previously treated with both standard and anti-EGFR treatment

Saved in:
Bibliographic Details
Title: 436TiP COLSTAR: Randomized, open-label, multicentre, phase III study comparing futuximab/modotuximab plus trifluridine/tipiracil to trifluridine/tipiracil in KRAS/NRAS and BRAF wild type (wt) metastatic colorectal cancer (mCRC) previously treated with both standard and anti-EGFR treatment
Authors: Ciardiello, F.1 (AUTHOR), Yoshino, T.2 (AUTHOR), Modest, D.P.3 (AUTHOR), Martin Fernandez, L.4 (AUTHOR), Roby, L.4 (AUTHOR), Fougeray, R.4 (AUTHOR), Lockhart, B.P.5 (AUTHOR), Tabernero, J.6 (AUTHOR)
Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS733-S734. 2p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2022.07.574